These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38757202)

  • 1. Successful use of empagliflozin in medically refractory post-bariatric surgery hypoglycaemia.
    Park YA; Chhabra M; Sim IW
    Intern Med J; 2024 May; 54(5):836-837. PubMed ID: 38757202
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
    Fitchett D; Inzucchi SE; Wanner C; Mattheus M; George JT; Vedin O; Zinman B; Johansen OE
    Eur Heart J; 2020 Jan; 41(2):209-217. PubMed ID: 31504427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
    Fitchett D; Inzucchi SE; Lachin JM; Wanner C; van de Borne P; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; George JT; Zinman B;
    J Am Coll Cardiol; 2018 Jan; 71(3):364-367. PubMed ID: 29348030
    [No Abstract]   [Full Text] [Related]  

  • 4. Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment.
    Klarskov CK; Holm Schultz H; Persson F; Møller Christensen T; Almdal TP; Snorgaard O; Bagge Hansen K; Pedersen-Bjergaard U; Lommer Kristensen P
    BMC Endocr Disord; 2020 Jun; 20(1):86. PubMed ID: 32539810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Empagliflozin: another of silent revolutioners].
    Kvapil M
    Vnitr Lek; 2014 Nov; 60(11):924-5. PubMed ID: 25612346
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
    Inzucchi SE; Kosiborod M; Fitchett D; Wanner C; Hehnke U; Kaspers S; George JT; Zinman B
    Circulation; 2018 Oct; 138(17):1904-1907. PubMed ID: 30354665
    [No Abstract]   [Full Text] [Related]  

  • 7. Empagliflozin Eliminates Refractory Ascites and Hepatic Hydrothorax in a Patient With Primary Biliary Cirrhosis.
    Kalambokis GN; Tsiakas I; Filippas-Ntekuan S; Christaki M; Despotis G; Milionis H
    Am J Gastroenterol; 2021 Mar; 116(3):618-619. PubMed ID: 33027081
    [No Abstract]   [Full Text] [Related]  

  • 8. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
    Levine MJ
    Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
    Savarese G; Sattar N; Januzzi J; Verma S; Lund LH; Fitchett D; Zeller C; George JT; Brueckmann M; Ofstad AP; Inzucchi SE; Wanner C; Zinman B; Butler J
    Circulation; 2019 Mar; 139(11):1458-1460. PubMed ID: 30855996
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus.
    Papazafiropoulou AK; Mpoumi L; Papantoniou S; Rallatou M; Antonopoulos S; Melidonis A
    Ann Afr Med; 2021; 20(2):154-155. PubMed ID: 34213486
    [No Abstract]   [Full Text] [Related]  

  • 11. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
    Katsiki N; Triposkiadis F
    Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Kappel BA; Lehrke M; Schütt K; Artati A; Adamski J; Lebherz C; Marx N
    Circulation; 2017 Sep; 136(10):969-972. PubMed ID: 28874423
    [No Abstract]   [Full Text] [Related]  

  • 13. Bolstering your armamentarium with SGLT2 inhibitors.
    Novak LM; Kruger DF
    Nurse Pract; 2017 Oct; 42(10):28-34. PubMed ID: 28926495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
    Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
    Mazer CD; Hare GMT; Connelly PW; Gilbert RE; Shehata N; Quan A; Teoh H; Leiter LA; Zinman B; Jüni P; Zuo F; Mistry N; Thorpe KE; Goldenberg RM; Yan AT; Connelly KA; Verma S
    Circulation; 2020 Feb; 141(8):704-707. PubMed ID: 31707794
    [No Abstract]   [Full Text] [Related]  

  • 16. New Medications for the Treatment of Diabetes.
    Garg SK; Giordano D
    Diabetes Technol Ther; 2019 Feb; 21(S1):S160-S171. PubMed ID: 30785325
    [No Abstract]   [Full Text] [Related]  

  • 17. [New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes].
    Rušavý Z
    Vnitr Lek; 2014 Nov; 60(11):926-7, 929-30. PubMed ID: 25600037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
    Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
    Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.